FRM
ANIP icon

Fox Run Management’s ANI Pharmaceuticals ANIP Stock Holding History

Fox Run Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,170
Closed -$487K – 892
2025
Q4 		$487K Sell
6,170
-2,320
-27% -$201K 0.08% 513
2025
Q3 		$778K Buy
+8,490
New +$692K 0.12% 303

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.72B AUM 1.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fox Run Management's ANIP Position: Q1 2026 in Review

Fox Run Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2026, closing a stake of 6,170 shares — an estimated $487K sold.

Fox Run Management first reported a position in ANIP in Q3 2025 and held it in 2 quarters. The position peaked at $778K in Q3 2025. 281 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Fox Run Management reported no remaining ANI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 6,170 ANI Pharmaceuticals shares in Q1 2026, an estimated $487K.
  • Fox Run Management first reported a position in ANI Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Fox Run Management's ANI Pharmaceuticals position peaked at $778K in Q3 2025.
  • 281 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.